Mucosal Kaposi sarcoma, a Rare Cancer Network study
Open Access
- 1 October 2012
- journal article
- Published by SAGE Publications in Rare Tumors
- Vol. 4 (4), 156-161
- https://doi.org/10.4081/rt.2012.e49
Abstract
Kaposi's sarcoma (KS) most often affect the skin but occasionally affect the mucosa of different anatomic sites. The management of mucosal KS is seldom described in the literature. Data from 15 eligible patients with mucosal KS treated between 1994 and 2008 in five institutions within three countries of the Rare Cancer Network group were collected. The inclusion criteria were as follows: age >16 years, confirmed pathological diagnosis, mucosal stages I and II, and a minimum of 6 months’ follow-up after treatment. Head and neck sites were the most common (66%). Eleven cases were HIV-positive. CD4 counts correlated with disease stage. Twelve patients had biopsy only while three patients underwent local resection. Radiotherapy (RT) was delivered whatever their CD4 status was. Median total radiation dose was 16.2 Gy (0–45) delivered in median 17 days (0–40) with four patients receiving no RT. Six patients underwent chemotherapy and received from 1 to 11 cycles of various regimens namely vinblastin, caelyx, bleomycine, or interferon, whatever their CD4 counts was. Five-year disease free survival were 81.6% and 75.0% in patients undergoing RT or not, respectively. Median survival was 66.9 months. Radiation-induced toxicity was at worse grade 1–2 and was manageable whatever patients’ HIV status. This small series of mucosal KSs revealed that relatively low-dose RT is overall safe and efficient in HIV-positive and negative patients. Since there are distant relapses either in multicentric cutaneous or visceral forms in head and neck cases, the role of systemic treatments may be worth investigations in addition to RT of localized disease. Surgery may be used for symptomatic lesions, with caution given the risk of bleeding.Keywords
This publication has 42 references indexed in Scilit:
- The Rare Cancer Network: Achievements from 1993 to 2012Rare Tumors, 2012
- A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Electrochemotherapy in the Treatment of Kaposi Sarcoma Cutaneous Lesions: A Two-Center Prospective Phase II TrialAnnals of Surgical Oncology, 2011
- Pharmacological management of Kaposi's sarcomaExpert Opinion on Pharmacotherapy, 2011
- Complete resolution of oral Kaposi’s sarcoma achieved by changing immunosuppression: a case reportThe Annals of The Royal College of Surgeons of England, 2010
- Update on classic Kaposi sarcoma therapy: New look at an old diseaseCritical Reviews in Oncology/Hematology, 2008
- Non‐AIDS Kaposi's sarcoma in the head and neck areaHead & Neck, 2008
- Targeting mTOR in HIV-Negative Classic Kaposi's SarcomaSarcoma, 2008
- Unusual presentation of oropharyngeal Kaposi's sarcomaHead & Neck, 2008
- The duration of local control of classic (non—AIDS-associated) Kaposi's sarcoma by radiotherapyJournal of the American Academy of Dermatology, 1988